DiaMedica Therapeutics Inc. (DMAC) Free cash flow
- Free cash flow · 12 months (USD): Value $-31.54M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-31.54M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-31.51M − $33.00K ≈ $-31.54M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-31.51M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.84× | Operating cash flow / net income. Period ending 2026-06-30. $-31.51M ÷ $-37.54M ≈ 0.84× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -31.51M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 33.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -31.54M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -37.54M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-31.54M | (m) | $-31.51M | $33.00K | (m) | (m) | (m) | $-37.54M | (m) | (m) | (m) | 0.84× |
| 2026-03-31 | $-31.03M | (m) | $-31.00M | $36.00K | (m) | (m) | (m) | $-35.10M | (m) | (m) | (m) | 0.88× |
| 2025-12-31 | $-29.10M | (m) | $-29.06M | $40.00K | (m) | (m) | (m) | $-32.77M | (m) | (m) | (m) | 0.89× |
| 2025-09-30 | $-27.77M | (m) | $-27.73M | $41.00K | (m) | (m) | (m) | $-31.93M | (m) | (m) | (m) | 0.87× |
| 2025-06-30 | $-25.68M | (m) | $-25.65M | $34.00K | (m) | (m) | (m) | $-29.58M | (m) | (m) | (m) | 0.87× |
| 2025-03-31 | $-22.60M | (m) | $-22.57M | $28.00K | (m) | (m) | (m) | $-27.00M | (m) | (m) | (m) | 0.84× |
| 2024-12-31 | $-22.10M | (m) | $-22.08M | $25.00K | (m) | (m) | (m) | $-24.44M | (m) | (m) | (m) | 0.90× |
| 2024-09-30 | $-19.48M | (m) | $-19.45M | $21.00K | (m) | (m) | (m) | $-21.70M | (m) | (m) | (m) | 0.90× |
| 2024-06-30 | $-19.80M | (m) | $-19.78M | $22.00K | (m) | (m) | (m) | $-19.90M | (m) | (m) | (m) | 0.99× |
| 2024-03-31 | $-20.32M | (m) | $-20.29M | $26.00K | (m) | (m) | (m) | $-19.26M | (m) | (m) | (m) | 1.05× |
| 2023-12-31 | $-18.75M | (m) | $-18.73M | $24.00K | (m) | (m) | (m) | $-19.38M | (m) | (m) | (m) | 0.97× |
| 2023-09-30 | $-17.73M | (m) | $-17.68M | $53.00K | (m) | (m) | (m) | $-17.97M | (m) | (m) | (m) | 0.98× |
| 2023-06-30 | $-15.33M | (m) | $-15.25M | $86.00K | (m) | (m) | (m) | $-16.56M | (m) | (m) | (m) | 0.92× |
| 2023-03-31 | $-12.80M | (m) | $-12.71M | $88.00K | (m) | (m) | (m) | $-15.44M | (m) | (m) | (m) | 0.82× |
| 2022-12-31 | $-11.59M | (m) | $-11.51M | $81.00K | (m) | (m) | (m) | $-13.68M | (m) | (m) | (m) | 0.84× |
| 2022-09-30 | $-11.61M | (m) | $-11.55M | $56.00K | (m) | (m) | (m) | $-13.17M | (m) | (m) | (m) | 0.88× |
| 2022-06-30 | $-12.25M | (m) | $-12.23M | $15.00K | (m) | (m) | (m) | $-13.56M | (m) | (m) | (m) | 0.90× |
| 2022-03-31 | $-11.84M | (m) | $-11.83M | $13.00K | (m) | (m) | (m) | $-13.48M | (m) | (m) | (m) | 0.88× |
| 2021-12-31 | $-12.27M | (m) | $-12.25M | $22.00K | (m) | (m) | (m) | $-13.59M | (m) | (m) | (m) | 0.90× |
| 2021-09-30 | $-12.52M | (m) | $-12.46M | $60.00K | (m) | (m) | (m) | $-14.55M | (m) | (m) | (m) | 0.86× |
| 2021-06-30 | $-11.82M | (m) | $-11.77M | $58.00K | (m) | (m) | (m) | $-14.29M | (m) | (m) | (m) | 0.82× |
| 2021-03-31 | $-10.57M | (m) | $-10.52M | $54.00K | (m) | (m) | (m) | $-13.49M | (m) | (m) | (m) | 0.78× |
| 2020-12-31 | $-9.23M | (m) | $-9.19M | $47.00K | (m) | (m) | (m) | $-12.29M | (m) | (m) | (m) | 0.75× |
| 2020-09-30 | (m) | (m) | $-8.03M | (m) | (m) | (m) | (m) | $-10.57M | (m) | (m) | (m) | 0.76× |
| 2020-06-30 | (m) | (m) | $-6.92M | (m) | (m) | (m) | (m) | $-9.83M | (m) | (m) | (m) | 0.70× |
| 2020-03-31 | (m) | (m) | $-8.95M | (m) | (m) | (m) | (m) | $-9.82M | (m) | (m) | (m) | 0.91× |
| 2019-12-31 | $-9.10M | (m) | $-9.10M | $2.00K | (m) | (m) | (m) | $-10.65M | (m) | (m) | (m) | 0.85× |
| 2019-09-30 | (m) | (m) | $-9.14M | (m) | (m) | (m) | (m) | $-10.13M | (m) | (m) | (m) | 0.90× |
| 2019-06-30 | (m) | (m) | $-9.74M | (m) | (m) | (m) | (m) | $-9.07M | (m) | (m) | (m) | 1.07× |
| 2019-03-31 | (m) | (m) | $-7.89M | (m) | (m) | (m) | (m) | $-8.34M | (m) | (m) | (m) | 0.95× |
| 2018-12-31 | $-5.75M | (m) | $-5.70M | $50.00K | (m) | (m) | (m) | $-5.73M | (m) | (m) | (m) | 0.99× |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-3.92M | (m) | $-3.90M | $22.00K | (m) | (m) | (m) | $-4.26M | (m) | (m) | (m) | 0.92× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |